Qiming Venture Partners

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.

BioHeng is a clinical biopharmaceutical and biotechnology Company focuses on novel immunotherapy and next-generation gene therapy development for treating cancers and various diseases. Founded in 2017, Bioheng has established a high standard GMP grade clinical translational center, and is leading in the field of cell engineering, proliferation and clinical applications. Particularly, Bioheng owns several cutting-edge patents plus extensive industry experience, and has built a complete, closed and automated production system in compliance with regulatory guidelines. In 2018, Bioheng has successfully raised tens of millions of RMB seeding fund from Simcere Pharmaceutical Group, aiming to accelerate the development of immunotherapy via integrating resources from both parties. Bioheng is dedicated to develop safer, effective and less expensive cell therapy drugs to benefit more patients.

GenEditBio is a biotechnology company dedicated to developing curative gene editing therapies for genetic disorders. It focuses on innovative in vivo gene editing tools and delivery systems.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

Complete Omics is a company focused on the development of multi-omics diagnostics for early disease detection, particularly in cancer. The firm specializes in creating personalized diagnosis and treatment platforms that leverage advanced technologies across various omics fields. With patented innovations, Complete Omics offers precision companion diagnostics that enhance the ability to conduct sensitive and specific health surveillance tests. By enabling researchers and pharmaceutical companies to utilize these sophisticated tools, Complete Omics aims to improve diagnosis and treatment outcomes in the field of oncology.

Biotree Technology is a high-tech enterprise that specializes in the application, consulting, and development of advanced research technologies within the life sciences sector. Focusing on mass spectrometry and metabolomics, the company provides comprehensive solutions for early detection and analysis in China. With a strong core team experienced in metabolomics, Biotree Technology offers services in scientific research, health testing, and industrial testing. The company is recognized for its innovation in metabolomics products and technology, holding several patents in the field. It has established itself as a leader in metabolomics detection and analysis, maintaining steady growth and profitability over the years. Through its biotechnological testing and consulting services, Biotree Technology assists clients in testing product quality and conducting various biotechnological research projects.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Biotree Technology is a high-tech enterprise that specializes in the application, consulting, and development of advanced research technologies within the life sciences sector. Focusing on mass spectrometry and metabolomics, the company provides comprehensive solutions for early detection and analysis in China. With a strong core team experienced in metabolomics, Biotree Technology offers services in scientific research, health testing, and industrial testing. The company is recognized for its innovation in metabolomics products and technology, holding several patents in the field. It has established itself as a leader in metabolomics detection and analysis, maintaining steady growth and profitability over the years. Through its biotechnological testing and consulting services, Biotree Technology assists clients in testing product quality and conducting various biotechnological research projects.

Ceptur Therapeutics is focused on developing innovative genetic medicines for patients with unmet medical needs. The company utilizes its proprietary U1 Adaptor technology to achieve non-genotoxic, long-lasting silencing of disease-causing genes, particularly in challenging tissues beyond the liver and central nervous system. This technology addresses the limitations of existing gene silencing methods and has potential applications in cancer treatment, allowing healthcare providers to offer new therapeutic options for various cancer types. Through its advancements, Ceptur aims to improve patient outcomes by providing effective solutions for difficult-to-treat conditions.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

GenEdit Inc., established in 2016 and headquartered in Berkeley, California, specializes in developing innovative genome editing tools. The company's core technology is CRISPR/Cas9, which enables precise therapeutic gene editing. GenEdit has further advanced this field by creating the NanoGalaxy™ platform, a proprietary non-viral delivery system that efficiently transports CRISPR/Cas9 to target tissues, overcoming previous delivery challenges. This platform systematically screens a library of nanoparticles to ensure safer and more effective delivery, making therapeutic gene editing easier, faster, and more accurate than traditional methods. GenEdit's ultimate goal is to facilitate the cure of previously incurable genetic diseases by providing physicians with powerful tools for gene therapy.

Genevide is a biotech company established in 2019 and based in Suzhou, Jiangsu, China. The company focuses on gene research and development, specifically addressing challenges in nucleic acid detection. Genevide has developed a molecular enzyme cycle screening platform that includes enzyme-mediated one-step sample processing technology and enzyme-mediated double exponential amplification nucleic acid detection technology. These innovations aim to enhance the accessibility and efficiency of nucleic acid detection for researchers.

Sanegene Bio is a biotechnology company focused on developing RNA interference (RNAi) therapeutics aimed at addressing unmet clinical needs across various therapeutic areas. Its innovative RNAi drug discovery platform targets disease-causing genes, effectively knocking them down to provide potential treatments for conditions such as cardiovascular and metabolic diseases, immunology-related disorders, and diseases affecting the nervous system. By leveraging advanced RNA technology, Sanegene Bio is capable of achieving specific delivery of multiple RNA drugs, enhancing the effectiveness of its therapeutic offerings for patients suffering from a range of health issues, including infectious diseases and eye conditions.

PlusLife Biotech, founded in 2017 and based in Guangzhou, China, focuses on creating innovative molecular diagnostic tools and gene treatment programs utilizing advanced gene technology. The company has developed a range of molecular point-of-care testing (POCT) detection cards and reagents designed for diverse applications, including human respiratory and reproductive tract infections, genotype detection, and pet disease detection. PlusLife Biotech aims to provide customers with cost-effective and user-friendly testing solutions, enhancing the accessibility and efficiency of medical diagnostics.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Abogen Biosciences, established in 2019 and headquartered in Jiangsu, China, specializes in the development of nucleic acid-based therapeutics, including RNA and DNA treatments, for combating cancer and infectious diseases.

Korro Bio Inc., established in 2018 and headquartered in Cambridge, Massachusetts, specializes in developing nucleic acid-based therapeutics targeting specific sequences in genetic code to treat rare diseases. The company's proprietary platform enables efficient and selective RNA editing, leveraging natural processes common to all multicellular organisms. Korro Bio aims to advance this technology to effect changes in protein structure and function across multiple tissues, expanding the reach of genetic medicines with additional precision and tunability by editing RNA instead of DNA.

Berry Genomics specializes in developing and commercializing genomics technologies for life sciences and clinical applications, focusing on next-generation sequencing (NGS) based tests for genetic diseases and cancer across various stages of life.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Berry Genomics specializes in developing and commercializing genomics technologies for life sciences and clinical applications, focusing on next-generation sequencing (NGS) based tests for genetic diseases and cancer across various stages of life.

Berry Oncology specializes in developing genetic diagnostic solutions for early detection and mid-to-late stage monitoring of various malignant tumors. Their offerings span from companion diagnostics to response monitoring and prognosis prediction for both targeted and immune therapies, aiming to enhance cancer prevention and tumor diagnosis globally. The company's primary mission is to facilitate early diagnosis and treatment of all tumors, ensuring precise care for patients. Berry Oncology aspires to become a global leader in early screening and diagnosis of tumors, particularly in China's tumor gene testing market.

Berry Genomics specializes in developing and commercializing genomics technologies for life sciences and clinical applications, focusing on next-generation sequencing (NGS) based tests for genetic diseases and cancer across various stages of life.

Amoy Diagnostics Co., Ltd. is a research and development focused diagnostic company that specializes in molecular diagnostics for oncology precision medicine. The company offers a portfolio of assays built on PCR, next‑generation sequencing, fluorescence in situ hybridization, and immunohistochemistry platforms. Its product range includes single‑gene testing kits, multi‑gene panels, NGS panels, and NGS analytical systems.

Amoy Diagnostics Co., Ltd. is a research and development focused diagnostic company that specializes in molecular diagnostics for oncology precision medicine. The company offers a portfolio of assays built on PCR, next‑generation sequencing, fluorescence in situ hybridization, and immunohistochemistry platforms. Its product range includes single‑gene testing kits, multi‑gene panels, NGS panels, and NGS analytical systems.

Berry Genomics specializes in developing and commercializing genomics technologies for life sciences and clinical applications, focusing on next-generation sequencing (NGS) based tests for genetic diseases and cancer across various stages of life.

OriGene Technologies, Inc. is a biotechnology company based in Rockville, Maryland, specializing in the development, manufacturing, and sale of genome-wide research and diagnostic products. Established in 1995, OriGene offers a comprehensive array of tools for academic, diagnostic, pharmaceutical, and biotech applications. Its product portfolio includes cDNA clones, shRNA and siRNA reagents, CRISPR/Cas9 genome editing tools, proteins, antibodies, and anatomic pathology products. Additionally, the company provides services such as gene synthesis, custom cloning, and assay development, supporting a variety of research areas including cancer biomarker research and stem cell research. OriGene's extensive resources aim to facilitate gene-based research, enabling researchers to validate antibodies and develop new drugs. The company's products are distributed globally through various channels, including online platforms.

Sangon Biotech Co. is a biotechnology company founded in 2003 as a Sino-foreign joint venture, specializing in the research and development of chemical synthesis of DNA. Over the years, Sangon has established itself as a key player in the global biotechnology market, known for its expertise in DNA synthesis, sequencing, and gene synthesis. The company has invested significantly in its infrastructure, including a manufacturing and industrial base in Songjiang Industrial Park. Sangon offers a wide range of products and services, including molecular biology kits, biochemicals, synthetic genes, oligos, peptide synthesis, enzymes, and laboratory consumables. By providing affordable life science research tools and services, Sangon supports researchers in advancing basic research and product development in the life sciences field.

AusperBio is a clinical-stage biopharmaceutical company focused on developing innovative treatments for hepatitis B and advancing oligonucleotide therapeutics. Utilizing its proprietary Med-Oligo™ ASO platform, AusperBio aims to deliver effective targeted therapies that leverage antisense oligonucleotide technology. The company is dedicated to transforming the treatment landscape for hepatitis B, with an emphasis on finding a cure and providing protection through novel therapeutic approaches. Additionally, AusperBio's research extends to addressing a variety of diseases, including viral infections, metabolic conditions, genetic disorders, and immune diseases, thereby broadening the potential impact of its therapeutic innovations.